Galectin-3 (GAL-3), a β-galactoside–binding protein secreted by immune cells, recently was approved by the US Food and Drug Administration as a prognostic aid in patients with heart failure (HF).1 Experimentally, GAL-3 is associated with inflammation and tissue fibrosis,2,3,4,5,6 and it has been associated with myocardial fibrosis, ventricular remodeling, and left ventricular dysfunction.7,8 GAL-3 expression is increased in experimental cardiomyopathy.8,9,10,11 Plasma GAL-3 seems to be a prognostic marker of HF outcomes such as death, recurrent HF, and hospitalization for HF.12,13,14. Here, LGALS3 is linked to heart failure.